AbstractBackground and objectives: This study was undertaken to test the ability of Trima Accel® version 5.2 to simultaneously collect concentrated high‐dose leukoreduced platelet products and double doses of plasma. Materials and methods: Random volunteers (18–65 years of age) with preprocedure platelet counts above 270 × 103/μl were recruited among the blood center's apheresis donors. All complied with the center's donor selection criteria. Results: One hundred fourteen (114) collections were performed. Depending on which definition of single platelet dose is used (2.0 × 1011 as prevalent standard in most European countries, and 3.0 × 1011 as prevalent standard in the United States and Canada) in 107/114 (single dose = 2.0 × 1011) and 39/114 (single dose = 3.0 × 1011) instances, a triple platelet product was obtained. In 87 cases (76%), a double plasmaproduct (>430 ml) was collected, and in seven cases (6%), a single plasma product (>220 ml) was collected. In 20 procedures, only platelets without concurrent plasma were collected (18%). Overall procedure time was 87 ± 13 min and average platelet yield per procedure was 8.5 ± 1.4 × 1011 (final storage concentration, 1,279 ± 153 × 103/μl). The median residual leukocyte content per transfusion dose was 0.13 × 106 (0.02–0.98 × 106) for a single dose of 2.0 × 1011 and 0.14 × 106 (0.02–0.98 × 106) for a single dose of 3.0 × 1011. Conclusions: Trima Accel® version 5.2 allows for collection of concentrated high yield platelet products. It offers high productivity and reliably achieves the configured yield targets. Leukoreduction performance complied with both US and EU legal requirements. Collection as hyperconcentrates furthermore allowed for concurrent collection of double dose plasma in the majority of the procedures. J. Clin. Apheresis, 2012. © 2012 Wiley Periodicals, Inc.